Note: Page references in *italics* refer to Figures; those in **bold** refer to Tables and Boxes

ablative procedures
- in CIN management 190
abnormal fetal karyotype
- as risk for RPL 133
abnormal menstrual bleeding 13–20 see also heavy menstrual bleeding (HMB)
- background 13–14, 13
- case scenario 13
abnormal placentation
- suspected
- tests for 552–3
abnormal uterine bleeding (AUB)
- defined 13
- FIGO on 13
abortion
- failed 26–7
- induced 21–32 see also induced abortion
- medical evaluation prior to 22
- pregnancies ending in 89
- spontaneous
- incidence of 33
abuse
- substance see substance abuse
acanthosis nigrans (AN)
- PCOS and 122–3, 122
acceleration
- defined 498, 499, 499
- in FHR
- physiology of 502
ACCP
- on VTE prevention during pregnancy 359, 361
ACE inhibitors see angiotensin-converting enzyme (ACE) inhibitors
acne
- isotretinoin for 207
- PCOS and 122, 122
ACOG see American College of Obstetricians and Gynecologists (ACOG)
ACOG/SMFM Obstetric Care Consensus 569
acquired cardiac disease 267–73
antepartum management of 268–9
- case scenario 267–8
- causes of 268
- clinical questions 268–73
acquired valvular lesions
- in pregnant women
- causes of 268
Actim PROM 398
active labor
- centimeter progression during 570
- initiation of 570
active management of risk in pregnancy at term (AMORIPAT) 528
active management of third stage of labor (AMTLS) 569
- benefits of 576–7, 576
- described 576–7, 576
- oxytocin in 576–9, 576, 578 see also oxytocin, in AMTLS
- TXA in 578
acupuncture
- in endometriosis pain management 79
- in HG management 228
- in post-term pregnancy management 436
acute anemia
- HMB and 15
acute glomerulonephritis
- pre-eclampsia vs. 292
acute phase arrest
- diagnosis of 570, 570
acyclovir
- for recurrent HSV infection 58, 58
adenocarcinoma-in-situ (AIS)
- case scenario 189
- progression to cancer
- risk factors for 192
- recurrence of
- risk factors for 192
adenomyomectomy
- in adenomyosis pain management 81
adenomyosis 75–87
- background 76
amniocentesis
in NTDs detection 220
for pregnant women at high risk for aneuploidy 218–19
amnioreduction (AR)
in polyhydramnios management 445–6
amniotic fluid (AF)
excessive see polyhydramnios
amniotic fluid (AF) abnormalities
perinatal outcome related to ultrasound in detection of 444, 444
amniotic fluid (AF) volume
background 443
described 443
disorders of 443–9 see also polyhydramnios
case scenario 443, 447
clinical questions 443–7
amniotomy
in cervical ripening 531, 532
AmniSure ROM Test 398
AMORIPAT see active management of risk in pregnancy at term (AMORIPAT)
AMTSL see active management of third stage of labor (AMTS)
AN see acanthosis nigra (AN)
analgesics
for CPP 52, 53
anemia
acute HMB and 15
blood loss management of 336, 336
anesthesia/anesthetics
for cesarean delivery in obese women 595–6
conduction labor courses related to 537
aneuploidy
pregnant women at risk for cfDNA analysis for 213–14
prenatal diagnosis for 213–23 see also prenatal diagnosis screening for 213
angiotensin-converting enzyme (ACE) inhibitors
fetal effects of 238, 239, 238
antepartum corticosteroids 2
in reducing morbidity and mortality from preterm birth 388, 390, 391
antepartum factors
impact on uterine rupture 420
antepartum hemorrhage (APH) 407–17
background 407
case scenario 407, 411, 413
causes of 407
clinical questions 407–11
defined 407
management of 407
prevalence of 407
undetermined/unexplained expectant management for 413
antepartum/intrapartum fetal surveillance 495–511
introduction 495
anti-androgens
antianxietyotics
  during pregnancy 206
antibiotic prophylaxis
  for cesarean delivery in obese women 594–5
antibiotics
  prophylactic see prophylactic antibiotics
antibody screen
  in women with EP 42
anticoagulant therapy
  for RPL 138–40, 139
antidepressant(s)
  breastfeeding while taking 380
  discontinuing among women who wish to or have recently conceived 378–8
  during pregnancy 207
antiemetics
  in pregnancy 228, 229
antiepileptic drugs (AEDs)
  during pregnancy
    concerns related to 316–17
    pharmacokinetic changes related to 316
antifibrinolytics
  for HMB 15–16
antihypertensive agents
  in preconception care 204–5
antioxidants
  in FGR management and prevention 457
antiphospholipid antibodies
  pre-eclampsia and 257
antiphospholipid syndrome (APS) 135–7, 138
β-hCG for 325–33
  case scenarios 131, 325–6
  catastrophic see catastrophic antiphospholipid syndrome (CAPS)
classification criteria for 327–8, 327
  clinical presentation of 326–7
  clinical questions 326–30
  definite 327–8, 327
  diagnosis of 326
  introduction 325
obstetric
  case scenario 325
  possible or probable 325–6, 328
  during pregnancy
    complications related to 326–7
    considerations related to 330–1
    management of 136–41, 138, 139, 140, 328–9
    “refractory obstetric” management of 329–30
  as risk factor for RPL 133–4
  thrombotic
    case scenario 325
antipsychotics
  during lactation 380–1
  during pregnancy 206
antithrombin deficiency (ATD)
  during pregnancy 356, 356, 357
aortic disease
  congenital
    in pregnancy 276
aortopathies
  in pregnancy 275
APH see antepartum hemorrhage (APH)
appendicitis
  possible
    exploratory surgery for 372
    in pregnancy 372
    in pregnancy 369–73
    background 369–70
    clinical questions 370–3, 370, 371
    delay in treatment of 372–3
    diagnosis of 370–2, 370, 371
    maternal and fetal risks associated with 372–3
APS see antiphospholipid syndrome (APS)
AR see amnioreduction (AR)
Arias-Stella reaction 36
aromatase inhibitors
  in endometriosis pain management 78–9
  for unexplained subfertility 147–8
arrest of labor
  defined 535
arterial ligation
  in PPH management 549
artificial valves
  during pregnancy 270–1
ARTs see assisted reproductive technologies (ARTs)
ASDs see atrioventricular septal defects (ASDs)
Asherman syndrome 550
aspiration
  vacuum induced abortion by 23, 24
aspirin
  for hereditary thrombophilias 139
  low-dose
    in FGR management and prevention 457
    in reducing risk of pre-eclampsia 257
  for patients with RPL and APS 136, 139
ASRM see American Society of Reproductive Medicine (ASRM)
assisted reproductive technologies (ARTs)
  EP related to 33, 35
  heterotopic pregnancy and 33
  twins after 467
  zygotic splitting after 467
asthma 247–53
background 247
  case scenario 247
  clinical questions 247–51
  general search strategy 247
  pregnant women with
    agents impacting outcomes of 249–51, 250
    congenital anomalies 248, 248
    fetal outcomes related to 247–8, 248
    management of 249–51, 250
    outcomes related to 248–51, 250
    risk factors related to 247–8, 248
antiphospholipid syndrome (APS) (continued)
stillbirth related to 248, 248
Atad double-balloon device
in cervical ripening 532
ATD see antithrombin deficiency (ATD)
atrioventricular septal defects (ASDs)
in pregnancy 273, 274
AUB see abnormal uterine bleeding (AUB)
augmentation of labor 527–37
background 534–5
case scenario 534
clinical questions 535–7
impact on uterine rupture 422, 423–6
auscultation
intermittent FHR
vs. randomized trials of EFM 495
autopsy
for stillbirth 481–2
balloon catheters
transcervical
in cervical ripening 531, 532
balloon tamponade
in PPH management 549
barrier methods
in contraception 94
baseline
defined 497, 498, 499
baseline FHR
defined 497, 498, 499
physiology of 502
bazedoxifene (BZA)
in menopause 158–9
bed rest
in preterm labor management 392
benzodiazepine(s)
during lactation 381
during pregnancy 206–7
beta-agonists
inhaled
impact on pregnancy women with asthma 250, 251
β-hCG
measurements of
in EP 33
beta subunit of human chorionic gonadotropin (β-hCG) see β-hCG
bimanual uterine compression
in PPH management 548–9
biophysical profiles (BPPs)
in antepartum surveillance of growth-restricted fetuses
perinatal outcomes of 453
bipolar I disorder
risk factors for 378
symptoms of 378
birth(s)
cesarean see also cesarean delivery
preterm 40
TOL after previous 419
multiple 467–77 see also multiple pregnancies and births premature
defined 397
preterm see preterm birth
vaginal see vaginal birth
birth control
methods of 89
birthweight
low see low–birthweight (LBW) infants
very low see very low–birthweight (VLBW) infants
birthweight discordance
defined 472
in multiples 472
Bishop score
modified 530, 530
bleeding see also hemorrhage
menstrual see menstrual bleeding
postpartum 545–57 see also postpartum hemorrhage (PPH)
vaginal see vaginal bleeding
in von Willebrand disease
management of 338–9, 338
blood loss anemia
management of 336, 336
blue cohosh
in post-term pregnancy management 436
B-Lynch uterine compression suture
in PPH management 549, 550
BMI see body mass index (BMI)
body mass index (BMI)
cesarean delivery by women with high 593
impact on emergency contraception 94
impact on uterine rupture 420–1
in pregnant women 569, 571
bone loss
menopause and 158
BPPs see biophysical profiles (BPPs)
breastfeeding
antidepressant use while 380
psychiatric illness in women who are
medication concentration in breast milk 380–1
breast milk
medication concentration in 380–1
breech presentation
delivery with 521
in later third trimester
risk factors for 521
breech vaginal delivery
cesarean delivery vs.
for third trimester malpresentation 521–2
bulimia nervosa
HG related to 225
“bundle”
defined 563
BZA see bazedoxifene (BZA)
cancer(s) see also specific types
AIS progression to
risk factors for 192
cervical 165–72
cervical dysplasia progression to
risk factors for 192
CIN progression to
cardiac disease
risk factors for 192
endometrial 181–8
vaginal 173–80
vulvar 173–80
vulvovaginal 174–5, 174
cannabis use
during pregnancy 207–8
CAPS see catastrophic antiphospholipid syndrome (CAPS)
carbimazole
for Graves’ disease in pregnancy 309, 310
cardiac disease
acquired 267–73 see also acquired cardiac disease
obstetric and fetal risks in women with 275
epidemiology of 265–6
preconception care in management and prevention of 205
preconception counseling for women with 268
pregnant women with
antibiotic prophylaxis for 272
risk assessment models for 266–7, 266
WHO classification system on 267
cardiomyopathy
dilated 279
hypertrophic 278
peripartum 277–80 see also peripartum cardiomyopathy
(CPCM) in pregnancy 277–80
case scenario 277
delivery and monitoring methods for 280
postpartum care for 280
risk factors for 279
restrictive 278–9
typical forms of
management of 279–80
vs. PPCM 278–9
types of 278–9
cardiopulmonary arrest 565–6
case scenario 565
in pregnant women
immediate vs. delayed perimortem/resuscitative cesarean
section for 565–6
cardiovascular disease (CVD) 265–86 see also specific diseases, e.g.,
congenital heart disease
acquired cardiac disease 267–73
cardiomyopathy 277–80
congenital heart disease 273–7
contraceptive use and 92
introduction 265–7
long-term maternal risk of
postpartum counseling related to 261–2
menopause and 158
PPCM 277–80
“care bundle”
defined 563
in management of VTE events in pregnant women admitted to hospital 562–5
CARPREG risk prediction score
for cardiac event during pregnancy 266, 266
catastrophic antiphospholipid syndrome (CAPS)
classification criteria for 328, 328
described 327
during pregnancy
management of 330
CCT see controlled cord traction (CCT)
CDC see Centers for Disease Control and Prevention (CDC)
CD4 counts
low
vulvovaginal cancers related to 174
cell-free fetal DNA (cfDNA) analysis
for pregnant women at risk for aneuploidy 213–14
in Trisomy 21 and Trisomy 18 detection 213–14
Centers for Disease Control and Prevention (CDC)
Preconception Health and Health Care Initiative of 201, 202
USMEC of 92
central nervous system (CNS)
in CPP 50–1
cephalic presentation
ECV in effort to turn fetus into 521
cervical cancer 165–72
background 165, 165
case scenario 165
causes of 165
clinical presentation of 165
clinical questions 166–9
early-stage
treatment of 168–9, 169
HPV and 165, 167
incidence of 165
prevalence of 165
risk factors for 166–7, 166
squamous cell carcinoma 165
staging of 168–9, 169
symptoms of 165
treatment of
stage-related 168–9, 169
types of 167
cervical cerclage
PPROM management related to 402
cervical dysplasia 189–95 see also cervical intraepithelial neoplasia
(CIN)
background 189
case scenario 189
causes of 189
clinical questions 189–93
defined 189
general search strategy 189–90
management of
in pregnant patients 193
risks of preterm delivery after 192–3
prevention of
HPV vaccines in 191–2
progression to cancer
risk factors for 192
recurrence of
risk factors for 192
risk factors for 191
cervical ectopic pregnancy (EP)
cervical ectopic pregnancy (EP)  (continued)
local therapy in  42
cervical injury
  induced abortion and  25–6
cervical intraepithelial neoplasia (CIN)  189–95 see also cervical dysplasia
AIS–related
  prevalence of  190–1
categories of  190
clinical questions  189–93
defined  189
detection of
  diagnostic tests vs. cervical cytology in  167–8
HPV and  165, 167, 189–95 see also human papillomavirus (HPV)
prevention of
  HPV vaccines in  191–2
progression to cancer
  risk factors for  192
recurrence of
  risk factors for  192
risk factors for  191
treatment of
  ablative procedures in  190
CKC in  191
costs related to  190
cryotherapy in  191
excisional procedures in  191
laser ablation in  191
laser conization in  191
LEEP in  191
LLETZ in  191
risks of preterm delivery after  192–3
cervical ripening
  described  531
methods of  531–3, 531
cesarean birth
  preterm
    uterine rupture related to  420
    TOL after previous  419
cesarean delivery
  BMI risks related to  593
breach vaginal delivery  vs.
  for third trimester malpresentation  521–2
complications following  593
induction of labor and  528–9
oxytocin related to  533–4
maternal–fetal complications of
  in obese women  593–9
anesthesia considerations  595–6
antibiotic prophylaxis for  594–5
case scenario  593
clinical questions  593–7
LMWH for  596–7
technical surgical aspects at  594
thromboprophylaxis for  596–7
for pregnant women with cardiopulmonary arrest  565–6
prevalence of  583
prophylactic induction of labor for fetal macrosomia in
decreasing risk for  458, 460
in shoulder dystocia prevention  460, 460
technical surgical aspects at  594
vacuum extraction at
  safety considerations  587
vaginal birth after  419–30 see also vaginal birth after cesarean (VBAC) delivery
cfDNA see cell-free fetal DNA (cfDNA) analysis
chlamydia
  clinical presentations of  55–6
  diagnosis of  56–7
  treatment of  57–8
cholecystectomy
  laparoscopic
    for cholelithiasis in pregnancy  366–7
  open
    for cholelithiasis in pregnancy  366–7
cholelithiasis
  described  365
  in pregnancy  365–7
    clinical questions  365–7
  described  365
  diagnosis of  365–6
  management of  366–7
chorionic villous sampling (CVS)
  for pregnant women at high risk for aneuploidy  218
chromosome microarray analysis
  in fetal anomalies diagnostic testing  487–8
  for pregnant women at high risk for aneuploidy  219
chronic diseases
  management of
    medications in  206–7
    preconception care in  203–6
chronic hypertension  258
preconception care for women with  204–5
chronic kidney disease (CKD)
  classification of  288–9, 288
  in pregnant women  287–96
    background 288–90, 288–90
  considerations  288–90, 288–90
  impact of  289, 289
  management of  290–4
  perinatal morbidity and mortality associated with  287
  prevalence of  287
chronic pelvic pain (CPP)  49–54
causes of
  laparoscopy in identifying  51–2
  clinical questions  50–2
CNS in  50–1
defined  49
general search strategy  50
initial consultation influencing  51
management of  52, 53, 53
  consensus on approach to  49–50
  musculo-skeletal abnormalities in women of reproductive age
    with  51
  presentation of  49
chronic salpingitis
cigarette smoking during pregnancy see smoking
CIL see complete inguinofemoral lymphadenectomy (CIL)
CIN see cervical intraepithelial neoplasia (CIN)
CIN 1 described 190
CIN 2 described 190
reurrence risk and progression to cancer in women 192
CIN 3 described 190
reurrence risk and progression to cancer in women 192
CKC see cold knife conization (CKC)
CKD see chronic kidney disease (CKD)
clinical scoring systems
  types of 561, 564
clophiphene citrate
  for unexplained subfertility 146–7
CMV see cytomegalovirus (CMV)
CNS see central nervous system (CNS)
Cochrane Collaboration 2, 5, 5
COCs see combined oral contraceptives (COCs)
cognition
  menopause effects on 158
cognitive decline
  menopause and 158
cold knife conization (CKC)
  in CIN management 191
Collaborative Perinatal Project 569
Collaborative Review of Sterilization (CREST) 90
colpocleisis
  in uterine prolapse management 102–3
combined first and second trimester screening
  for pregnant women with low or average risk for aneuploidy
  in Trisomy 21 and Trisomy 18 detection 215–16, 215
combined oral contraceptives (COCs)
  in endometriosis pain management 78
  for HMB 16, 17
  in PCOS management 123–4
complementary and alternative medicine
  in post-term pregnancy management 435–6
complete inguinofemoral lymphadenectomy (CIL)
  in early-stage vulvar cancer management 175–6
compression sutures
  in PPH management 549–50, 550
computed tomography (CT)
  in appendicitis in pregnancy 371–2, 371
computed tomography pulmonary angiogram (CTPA)
  for VTE in pregnancy 561, 563
conception(s)
  DZ 467–8
  MZ 467–8
  retained products of
    induced abortion and 26
  condoms
  in contraception 94
  conduction anesthesia
  labor courses related to 537
Confidential Enquiries into Maternal Death 595
congenital anomalies
  oligohydramnios 488
  single umbilical artery 488
  stillbirth related to 490
  in twins 488
  in women with asthma 248, 248
congenital aortic disease
  in pregnancy 276
congenital heart disease 273–7
  clinical questions 273–7
  preconception care in management and prevention of 205
  in pregnant women
    antepartum management for 273
    case scenario 273
    maternal risks associated with 274–5
    obstetric, fetal, and neonatal risks associated with 275–6
    postpartum care for 277
    preferred labor and delivery methods for 276
    recurrence risk for subsequent child 273–4
congenital pulmonary airway malformation (CPAM)
  clinical questions 514–18
  defined 513
  diagnosis of
    prognosis related to 517–18
    hydrops fetalis with 513–19
    case scenario 513–14, 514, 515
    incidence of 513
    prognosis of 513
    treatment of 514, 515
    in-utero 518
    types of 518
conjoined twins 467
Consortium on Safe Labor (CSL) 569
contingent screening
  for pregnant women with low or average risk for aneuploidy
  in Trisomy 21 and Trisomy 18 detection 216
contraception 89–97 see also contraceptive use
  background 89
  barrier methods 94
  case scenario 89, 94–5
  clinical questions 89–93
  effectiveness of
    determinants of 90–1, 91
  emergency 94
  general search strategy 90
  LARC methods 89, 92
  non–LARC methods 92–3
contraceptive(s)
  combined oral see combined oral contraceptives (COCs)
  oral
    in endometriosis pain management 78
    risk factors associated with 92
  Contraceptive Choice Project 89
  contraceptive methods see also specific types
    after induced abortion 27–8
  contraceptive use see also contraception
  cardiovascular disease and 92
  medical eligibility criteria for 91–2
contraceptive use see also contraception (continued)
smoking and 92
unintended pregnancy during 91, 91
controlled cord traction (CCT)
in third stage of labor 576, 577
“Core Principles and Values of Effective Team-Based Health Care,” 559
corticosteroids
antenatal 2
in reducing morbidity and mortality from preterm birth 388, 390, 391
in HG management 230
inhaled
impact on pregnant women with asthma 249–51, 250
in PPROM management 399–400
Coumadin
during pregnancy 206
Council on Patient Safety in Women’s Healthcare 563
counseling
fertility desires–related 90
on long-term health risks associated with PCOS 125–6, 126
postpartum
on long-term maternal risk of CVD 261–2
preconception
for women with cardiac disease 268
for women with diabetes 203–4
pregnancy spacing and limiting–related 90
prior to induced abortion 22
sterilization methods–related 90
CPAM see congenital pulmonary airway malformation (CPAM)
CPP see chronic pelvic pain (CPP)
CREST see Collaborative Review of Sterilization (CREST)
cryotherapy
in CIN management 191
CSL see Consortium on Safe Labor (CSL)
CT see computed tomography (CT)
CTPA see computed tomography pulmonary angiogram (CTPA)
cultoplasty
McCall
in pelvic organ prolapse management 103
CVD see cardiovascular disease (CVD)
CVS see chorionic villous sampling (CVS)
cyanotic heart disease
obstetric and fetal risks in women with
oxygen saturation in assessing 275
cystocele repair 104
cystoscopy
in pelvic organ prolapse repair 105
cytokine modulation
for unexplained RPL 140
cytomegalovirus (CMV)
in pregnancy 343–5, 344, 344, 345, 345
level of evidence 350
danazol
in adenomyosis pain management 79
in endometriosis pain management 79
DC placenta see dichorionic (DC) placenta
D&E see dilatation and evacuation (D&E)
deceleration(s)
defined 498, 499–500, 499, 501, 500
early 498, 499–500, 500
in FHR
physiology of 502–3, 503
late 498, 499, 500, 500
prolonged 498, 499, 500
variable 498, 499, 500, 501
deeply infiltrating endometriosis (DIE)
laparoscopic management of 80
prevalence of 76
deep vein thrombosis (DVT)
case scenario 355
during pregnancy
diagnosis of 357
delayed postpartum pre-eclampsia
defined 256–7
delivery see also labor and delivery
cardiomyopathy in 280
forceps vs. vacuum 583–4, 585
operative vaginal 583–91 see also operative vaginal delivery (OVD)
spontaneous 569–81 see also spontaneous delivery
VBAC 419–30 see also vaginal birth after cesarean (VBAC) delivery
depression
menopause and 157–8
postpartum 377
pregnancy-related 377–84
case scenario 377
clinical questions 377–81
prevalence of 377
psychiatric disease risk factors associated with 378
in women who wish to or have recently conceived
discontinuance of psychiatric medications by 377–8
DES see diethylstilboestrol (DES)
diabetes mellitus (DM) 297–302 see also gestational diabetes mellitus (GDM)
case scenario 297
clinical questions 297–302
gestational see gestational diabetes mellitus (GDM)
preconception counseling for women with 203–4
pregestational
preconception control of 203–4
in pregnancy
types of 297, 298
White classification for 297, 298
diabetic nephropathy
in pregnancy 291
dialysis
for CKD in pregnancy 292–3
dichorionic (DC) placenta 467–8
DIE see deeply infiltrating endometriosis (DIE) diet
in HG management 228
diethylstilboestrol (DES) 2
diffuse adenomyosis 76
dilatation and evacuation (D&E)
induced abortion by 24–5
for mid-trimester induction of labor 538, 538
dilated cardiomyopathy 279
Index 609

dilator(s)
  hygroscopic
    in cervical ripening 531, 532
dimenhydrinate
  in HG management 228, 229
dizygotic (DZ) conceptions 467–8
DM see diabetes mellitus (DM)
Doppler studies
  in identifying growth-restricted fetuses at risk for adverse pregnancy outcomes 453–6, 454, 455, 456
doxylamine
  in HG management 229
droperidol
  in HG management 230
drug(s) see also specific types and medication(s)
drug absorption
  physiologic changes during pregnancy effects on 234, 235
drug disposition
  physiologic changes during pregnancy effects on 234–6, 235
drug distribution
  physiologic changes during pregnancy effects on 234, 235
drug elimination
  physiologic changes during pregnancy effects on 235, 236
drug metabolism
  physiologic changes during pregnancy effects on 234–6, 235
drug toxicities
  fetal 238, 239
drug use
  recreational
    preconception care related to 207–8
D-transposition of great arteries
  in pregnancy 274
L-transposition of great arteries vs. 275
duloxetine
  for CPP 52, 53
duplex compression sonography
  for VTE in pregnancy 561, 563
DVT see deep vein thrombosis (DVT)
dysfunctional uterine bleeding 13
dysplasia(s)
  cervical 189–95 see also cervical intraepithelial neoplasia (CIN); CIN
dystocia
  shoulder
    cesarean delivery in prevention of 460, 460
DZ conceptions see dizygotic (DZ) conceptions
eye deceleration
  defined 498, 499–500, 500
  physiology of 502
eye miscarriage
  recurrent
    APS and 326
  “Early Obstetrical Warning System”
    in management of VTE events in pregnant women admitted to hospital 562–5
EBM see evidence-based medicine (EBM)
echocardiography
  fetal 489
eclampsia
  in mothers of multiple gestations 468, 469
ectopic pregnancy (EP) 33–47
  ARTs and 33, 35
  background 33
  causes of 35–6
  cervical
    local therapy in 42
    clinical questions 34–9
    defined 33
    described 35
    diagnosis of 36–8
    epidemiology of 34
    heterotopic
      local therapy in 42
      historical perspective 34
      incidence of 34
    interstitial
      local therapy in 41
      management of 39–42
      expectant 42
      local therapy 41–2
      medical 40–1
      surgical 39–40
    miscarriage vs. 39
    morbidity and mortality effects of 34
    ovarian
      local therapy in 42
      prevalence of 33
      PUL 38
      Rh status and antibody screen in women with 42
      risk factors for 34–5
      sites of 35
      symptoms of 35–8
  ectopic pregnancy (EP) rupture 36
  ECV see external cephalic version (ECV)
  EFM see electronic fetal heart rate monitoring (EFM)
  EFW see estimated fetal weight (EFW)
electronic fetal heart rate monitoring (EFM) see also under fetal heart rate (FHR)
  adjunct methods of 508–9
  background 495
  criteria for hypoxic neurologic injury 504–5, 505, 505
  interpretation of 503–5, 504, 504, 505, 505
  interruption of oxygen transfer from environment to fetus during 503–4, 504, 504
  management with 505–8, 506, 507
  confirm FHR and uterine activity 505, 506
  evaluate FHR components 505–6, 507
  expectant management vs. delivery 508
  re-evaluate FHR tracing 506–8, 506, 507
  principles of 504, 505
  randomized trials of vs. intermittent FHR auscultation 495
  embryonic anomalies
    EP and 35–6
    embryonic demise
      multiple pregnancies and births and 470
      emergency(ies)
    obstetric 559–68 see also specific types and obstetric emergencies
emergencies (continued)
emergency contraception 94
endocrine disorders
amenorrhea 109–13
endometrial ablation/resection
in HMB management 18, 18
endometrial cancer 181–8
case scenario 181
clinical questions 181–6
minimally invasive surgery for 183–4
premenopausal women with
Lynch syndrome in 186
ovarian removal in management of 184–5
prognosis of
lymph node dissection in 181–3
endometrioma
fertility effects of 81–2
endometriosis 75–87
ASRM staging system for 75
background 75–6
case scenario 75
clinical questions 76–83
deeply infiltrating 76, 80
evaluation for 77
hysterectomy for
ovarian preservation in women undergoing 83
infertility due to
management of 82
management of
peri-operative medical therapy in 82–3
manifestations of 75–6
pain symptoms of
management of 78–80
prevalence of 75
search strategy 76
severity of 75
sites of 75
types of 75–6
environmental toxins
preconception care related to 207–8
EP see ectopic pregnancy (EP)
EPCs program see US Evidence-based Practice Centers (EPCs)
Program
epilepsy
case scenario 315
clinical questions 316–17
grading of evidence 317
in pregnancy 315–17
background 315–16
fetal effects of 238–9, 239
prevalence of 315
search strategy 317
seizures in
causes of 316
ergometrine in AMTSL 577
ESHRE see European Society of Human Reproduction and Embryology (ESHRE)
ESHRE/ESGE classification system
of fibroids 63
Essure sterilization 93
estimated fetal weight (EFW)
case scenario 451
cesarean delivery and
in shoulder dystocia prevention 460, 460
in multiples 472
estrogen
for menopause 158
EURAP see International Registry of Antiepileptic Drugs and Pregnancy (EURAP)
European Society of Human Reproduction and Embryology (ESHRE)
on diagnostic tests for RPL 132, 133
evidence-based medicine (EBM)
defined 2
in OB/GYN 1–7
Cochrane Collaboration 5, 5
critically appraising studies and assessing strength of literature 4–5, 5
EPCs Program in 5–6
evidence-based resources 5, 5
formulating questions 3–4, 3
history 1–2
literature search and identifying relevant studies 4
steps in 3, 3
systematic review processes 2–3, 3, 2
USPSTF in 5–6
for RPL 140–1
evidence-based obstetrics
steps in 3, 3
excisional procedures
in CIN management 191
external cephalic version (ECV)
in effort to turn fetus into cephalic presentation 521
for third trimester malpresentation 522–3
failed abortion 26–7
fallopian tubes
EP within 35
famciclovir
for recurrent HSV infection 58, 58
FASTER trial 215–16, 490
female pattern hair loss
PCOS and 122, 122
Ferriman-Gallwey (FG) scoring system 120–2, 120–2, 122
fertility
endometrioma impact on 81–2
fibroids effect on 65, 65
fertility desires
counseling related to 90
fetal anomalies 487–94
background 487
case scenario 487
delivery mode and timing related to 489–90
diagnosis of
associated findings 488
chromosome microarray analysis in 487–8
imaging in 488–9
genetics of 487–8
introduction 487
management of
surgical 489
maternal risks associated with 490–1
prevalence of 487
risk factors for 490
termination due to 490
twinning and 488
types of 487
fetal assessment
multiple pregnancies and births and 472–3, 473
fetal death
APS and 326
fetal demise
intrauterine 479–85 see also stillbirth(s)
mid-trimester induction of labor secondary to
induction of labor vs. D&E for 538, 538
multiple pregnancies and births and 470
fetal drug toxicities 238, 239
fetal fibronectin (FFN)
in identifying risk factors for preterm birth 387
fetal growth
disorders of 451–65 see also specific disorders
background 451–2
case scenario 451, 460–1
clinical questions 452–60
multiple pregnancies and births impact on 472
fetal growth restriction (FGR) 451–65 see also fetal growth,
disorders of; growth-restricted fetuses
antepartum surveillance of
perinatal outcomes of 453
case scenario 451, 460–1
detection of
customized fetal growth curves in 452–3
management of
vitamins and antioxidants in 457
in multiples 472
neonatal health consequences of 458, 459
neurodevelopmental outcomes associated with 458, 459
prevention of
vitamins and antioxidants in 457
fetal heart rate (FHR)
baseline 502
decelerations 502–3, 503
variability 502
fetal karyotype
abnormal 133
fetal macrosomia
prophylactic induction of labor for 458, 460
fetal neuroprotection
magnesium sulfate in 400
fetal presentations
types of 521
fetal pulse oximetry
in intrapartum FHR monitoring 508
fetal thyroid disease 310
fetal warfarin syndrome 206
fetal well-being
in post-term pregnancy
tests for 434–5
fetus(es) see also under fetal
appendicitis in pregnancy risks to 372–3
breakthrough seizures impact on 316
cesarean delivery–related effects on 585, 586
congenital heart disease in pregnant women effects on 275–6
drug toxicities affecting 238, 239
echocardiography of 489
GDM effects on 298
Graves' disease in pregnancy effects on 308–10
growth-restricted see growth-restricted fetuses
HG effects on 226
induction of labor effects on 527–30, 528
maternal asthma effects on 247–8, 248
maternal pharmacotherapy effects on 238–9, 239, 238
MG effects on 321
multiple pregnancies and births impact on 469–73, 469, 471, 473
OVD–related effects on 585, 586
post-term pregnancy risk factors for 432, 433
size of
impact on uterine rupture 421
valvular lesions during pregnancy effects on 271
FFN see fetal fibronectin (FFN)
FGR see fetal growth restriction (FGR)
FHA see functional hypothalamic amenorrhea (FHA)
FHR see fetal heart rate (FHR)
fibroid(s) 63–74
causes of 64
classification of 63
diagnosis of 64, 65
epidemiology of 63
ESHRE/ESGE classification system of 63
evidence-based pregnancy outcomes related to 65–6, 65, 66
fertility effects of 65, 65
HLRCC and 64
introduction 63
management of
effects of 70
evidence-based 65, 67–9
LNG-IUDs 68
medical 67–8
fibroid(s) (continued)
  MRg-FUS in 68–9, 70
  surgical 67
  pressure/pain from 65
  prevalence of 63
  quantitative measures of 66–7
  uterine 63–74
  vaginal bleeding related to 65
fibronectin
  fetal
  in identifying risk factors for preterm birth 387
FIGO see International Federation of Gynecology and Obstetrics (FIGO)
First and Second Trimester Evaluation at Risk (FASTER) trial 215–16, 490
first stage of labor
  clinical questions 570–1, 570, 570
  Greenberg maternal age median length of 571
first trimester
  combined screening
    in pregnant women with low or average risk for aneuploidy 214–15, 214
  induced abortion during
    methods of 23–4
  vaginal bleeding in 33
focal adenomyosis 76
folic acid
  in NTDs prevention 202–3
fonaparinux
  for VTE during pregnancy 359
Fontan procedure 275
forceps delivery
  vacuum delivery vs. 583–4, 585
  “Friedman’s Curve” 569, 570
functional hypothalamic amenorrhea (FHA) 111

gabapentin
  for CPP 52
gastrointestinal disorders
  in pregnancy 365–76 see also specific disorders
    appendicitis 369–73
    cholelithiasis 365–7
    IBD 139
    ICP 368
    pancreatitis 367–8
GDM see gestational diabetes mellitus (GDM)
Gemeprost
  in induced abortion 23
  general gynecology 11–97
  genetics
    of fetal anomalies 487–8
  genital herpes simplex virus (HSV)
    clinical presentations of 56
    treatment of 58, 58
  genital tract infections
    background 55
    case scenario 55
    clinical presentations of 55–6
    during pregnancy 59
clinical questions 55–60
HSV 56–8, 58
  search strategy 55
  treatment of 57–60
    in pregnancy 59–60
genital warts
  clinical presentations of 56
  diagnosis of 57
  treatment of 58–9
genitourinary syndrome
  menopause and 137
gestational diabetes mellitus (GDM)
  causes of 297
  diagnostic criteria for 299–300, 299
  fetal effects of 298
  labor and delivery for women with 300
  maternal blood glucose monitoring and control during 300–1, 300
  monitoring in postpartum care 301
  in mothers of multiple gestations 468, 469
  in pregnancy
    types of 297, 298
    screening for 297–8
    treatment of 299–300
  gestational hypertension 257
  gestational transient thyrotoxicosis
    HG related to 226
glomerulonephritis
  acute
    vs. pre-eclampsia 292
  glucose intolerance
    classification of 297, 298
  GnRH agonists see gonadotropin releasing hormone (GnRH) agonists
gonadotropin(s)
  for unexplained subfertility 147
gonadotropin releasing hormone (GnRH) agonists
  in adenomyosis pain management 79
  in endometriosis pain management 78
  for fibroids 67, 70
gonorrhea
  clinical presentations of 55
  diagnosis of 56–7
  treatment of 57
  GRADE Working Group 4, 4
Grading of Recommendations Assessment, Development, and Evaluation (GRADE) Working Group 4, 4
Graves’ disease
  hyperthyroid disease due to
    prevalence of 308
  hypothyroid disease due to 303
  in pregnancy 308–10
    fetal risks associated with 308–10
    incidence of 308
    management of 308, 309
  thyroid function and antibody tests for 309–10
GRIT see Growth Restriction Intervention Trial (GRIT)
growth-restricted fetuses
  NSTs and BPPs in antepartum surveillance of
perinatal outcomes of 453
at risk for adverse pregnancy outcomes
Doppler studies in identifying 453–6, 454, 455, 456
timing of delivery for 456–7
Growth Restriction Intervention Trial (GRIT) 456–7
gynecology 9–195
general 11–97
hair loss
female pattern
PCOS and 122, 122
Hashimoto's thyroiditis 303
Hayman suture
in PPH management 549, 550
HCM see hypertrophic cardiomyopathy (HCM)
healthcare teams
in obstetric emergencies 566
heart disease see specific types and cardiac disease
heart valves
during pregnancy 270–1
heavy menstrual bleeding (HMB) 13–20
acute anemia with 15
background 13–14, 13
clinical questions 14–18
management of
antifibrinolytics in 15–16
COCs in 16, 17
endometrial ablation/resection in 18, 18
hysterectomy in 18, 18
injected/depot progestogens in 18
LNG-IUS in 16–18, 17
NSAIDs in 16, 17
oral progestogens in 15, 17
pharmacological 15–18, 17
tests for 14–15
Helicobacter pylori
HG related to 225–6
Hellin–Zellany rule
for twins, triplets, and quadruplets 467
HELLP (hemolysis, elevated liver enzymes, and low platelet) syndrome 256
hematologic disease 335–42 see also specific types
background 335
case scenario 335
clinical questions 335–40
hemoglobin disorders
during pregnancy
identification and management of 336–7, 337
hemolysis, elevated liver enzymes, and low platelet (HELLP) syndrome 256
hemorrhage see also bleeding
antepartum 407–17 see also antepartum hemorrhage (APH)
induced abortion and 26
postpartum 545–57 see also postpartum hemorrhage (PPH)
heparin(s)
for hereditary thrombophilias 139, 140
low-molecular weight see low-molecular weight heparin (LMWH)
during pregnancy 206
for unexplained RPL 139, 139
unfractionated
for VTE during pregnancy 358–9
herbal preparations
in HG management 228
in post-term pregnancy management 436
hereditary leiomyomatosis and renal cell carcinoma (HLRCC)
fibroids due to 64
hereditary thrombophilias
aspirin for 139
heparins for 139, 140
as risk factor for RPL 134
herpes simplex virus (HSV)
diagnosis of 57
genital
clinical presentations of 56
treatment of 58, 58
PPROM management related to 402
heterotopic ectopic pregnancy (EP)
local therapy in 42
heterotopic pregnancy 33–4
ARTs and 33
HG see hyperemesis gravidarum (HG)
high-order multiple pregnancies
hypertensive disorders in 468, 469
rare occurrence of 467
hirsutism
PCOS and 119–22, 120, 122
HIV
PPROM management related to 402
HLRCC see hereditary leiomyomatosis and renal cell carcinoma (HLRCC)
HMB see heavy menstrual bleeding (HMB)
hormone replacement therapy (HRT)
case scenario 155
for menopause 158–9
hormone supplementation
for RPL 137
for unexplained RPL 137
HPV see human papillomavirus (HPV)
HRT see hormone replacement therapy (HRT)
HSV see herpes simplex virus (HSV)
human immunodeficiency virus (HIV)
PPROM management related to 402
human papillomavirus (HPV)
cervical cancer related to 165, 167
CIN and 165, 167, 189–95
prevalence of 190–1
clinical questions 189–92
detection of
diagnostic tests vs. cervical cytology in 167–8
vulvovaginal cancers related to 174–5
human papillomavirus (HPV) vaccines
in CIN prevention 191–2
hydration
in preterm labor management 392
hydrops fetalis 513–19 see also congenital pulmonary airway malformation (CPAM)
aggravation of
hydrops fetalis (continued)
case scenario 513, 514
background 513–14
case scenario 513–14, 514, 515
classification of 513
clinical questions 514–18
CPAM and 513–19
deﬁned 513
ﬁndings associated with
case scenario 513, 514
non-immune
case scenario 513, 516
causes of 515, 516
diagnosis of 515, 517, 517
incidence of 515
prevalence of 513
survival rates 517, 518
vs. immune 513
hydroxychloroquine
for SLE 137
hygroscopic dilators
in cervical ripening 531, 532
hyperandrogenemia 118
hyperandrogenism 118
hypermegestis gravidarum (HG) 225–32
case scenario 225
causes of 225–6
deﬁned 225
described 225
diagnostic criteria 226–7, 227, 228
effects of 226
hyperthyroidism and 310–11
incidence of 225
laboratory abnormalities in 227
laboratory evaluation for 227
management of 227–30, 228
ACOG on 229
acupuncture in 228
diet in 228
herbal options in 228
hypnosis in 228
non-pharmacologic 228
pharmacologic 228, 229–30
recommendations 230
risk factors for 225
hypergonadotropic primary amenorrhea 110–11
hypergonadotropic secondary amenorrhea 111
hyperprolactinemia
treatment of 113
hypertension
chronic 258
preconception care for women with 204–5
gestational 257
pre-existing 258
superimposed pre-eclampsia on pregnancy-induced 257
hypertensive disorders of pregnancy 255–64
background 255–9, 256, 259
case scenario 255, 259–62, 259
categories of 255
clinical questions 259–62, 259
in high-order multiple pregnancies 468, 469
inpatient vs. outpatient evaluation for pre-eclampsia with 257
risk factors for
case scenario 259, 259
hyperthyroid disease 308–11
background 308
case scenario 308
causes of 308
prevalence of 308
hyperthyroidism
HG and 310–11
prevalence of 303
hypertrophic cardiomyopathy (HCM) 278
hypnosis
in HG management 228
hypothalamic amenorrhea 111
functional 111
hypothalamus
menopause effects on 156
hypothyroid disease
deﬁned 303
poor perinatal and childhood outcomes related to 305–6
in pregnancy
clinical questions 304–8
T4 dose in 304
thyroid function and antibody tests for 304–5
hypothyroidism
maternal subclinical 306–7
poor perinatal and childhood outcomes related to 305–6
in pregnancy
routine screening for 307
subclinical see subclinical hypothyroidism
treatment of 113
hypothyroxinemia
poor perinatal and childhood outcomes related to 305–6
hypoxic neurologic injury
criteria for 504–5, 505, 505
hysterectomy
in adenomyosis pain management 81
for endometriosis
ovarian preservation in women undergoing 83
for fibroids 67, 69
in HMB management 18, 18
number of
impact on uterine rupture 421
in placenta accreta management 553
alternatives to 553–4
in uterine prolapse management 102
hysterectomy
in uterine prolapse management 102
IBD see inﬂammatory bowel disease (IBD)
ICP see intrahepatic cholestasis of pregnancy (ICP)
idioopathic polyhydramnios
antenatal testing for diagnosis of fetal well-being related to 445
IHI see Institute for Healthcare Improvement (IHI)
immunosuppression
  vulvovaginal cancers related to 174–5, 174
immunotherapy
  for unexplained RPL 139–40
incontinence
  urinary 101–6
indomethacin
  in polyhydramnios management 446–7, 446
induced abortion 21–32
  background 21
  case scenario 21
  clinical questions 21–8
  contraceptive methods initiated after 27–8
  counseling prior to 22
  failed 26–7
  follow-up after 28
  medical assessments prior to 22
  medical “induction” 24
  methods of
    in first trimester 23–4
    in second trimester 24–5
  prevalence of 21
  risks associated with 25–7
  safety of 21
  subsequent reproduction outcomes related to 27
induction of labor 527–34
  background 527
  benefits of 527
  case scenario 527
  cervical ripening in 531–3, 531 see also specific methods, e.g., membrane sweeping
  clinical questions 527–34
  criteria for 527
  described 527
  failed outcome 534
  fetal and maternal outcomes related to 527–30, 528
  impact on uterine rupture 422, 423–6
  indications for 527–8, 528
  mid-trimester 537–8, 538 see also mid-trimester induction of labor
  oxytocin in 531, 533–4
  cesarean delivery and 533–4
  prevalence of 527
  preventive 528
  prophylactic
    for fetal macrosomia 458, 460
  prostaglandins in 531, 532–3
  risk-based 528
  risk factors for 527–8
  risk of cesarean delivery with 528–9
  success of
    tests in determination of 530–1, 530
  types of 528
infant(s)
  LBW
    multiple pregnancies and births and 472
  VLBW
    multiple pregnancies and births and 472
  infection(s) see also specific types
  genital tract 55–62 see also specific types and genital tract infections
  induced abortion and 26
  in pregnancy 343–54 see also specific types
    CMV 343–5
    level of evidence 350
    listeriosis 348–50
    parvovirus 345–6
    VZV 346–8, 347
  as risk factor for RPL 135
infertility
  adenomyosis and 76
  atypical APS laboratory test results 326
  endometriosis-related
    management of 82
  ovulatory
    PCOS and 124–5, 126
  PCOS and
    management of 125, 126
  unexplained 145–53 see also unexplained subfertility
  inflammatory bowel disease (IBD)
    in pregnancy 139
  informed consent
    for OVD 585
inguinofemoral lymph node dissection
  SLND vs.
    in early-stage vulvar cancer detection 175–7, 176
inhaled beta-agonists
  impact on pregnancy women with asthma 250, 251
inhaled corticosteroids
  impact on pregnant women with asthma 249–51, 250
injected/depot progestogens
  for HMB 18
Institute for Healthcare Improvement (IHI)
  on “bundle” 563
interdelivery interval
  impact on uterine rupture 421–2
intermittent FHR auscultation
  EFM vs. 495, 496
  randomized trials of EFM vs. 495
International Federation of Gynecology and Obstetrics (FIGO)
  on AUB 13
International Registry of Antiepileptic Drugs and Pregnancy (EURAP)
  on seizures in pregnancy 315–16
interoception care
  aim of 201
  rationale for 202
interoception period
  defined 201
interstitial ectopic pregnancy (EP)
  local therapy in 41
interval laparoscopic ligation 93
intrahepatic cholestasis of pregnancy (ICP) 368, 479
  case scenario 482
  causes of 482
  defined 482
  management of
    RCOG on 483
intrahepatic cholestasis of pregnancy (ICP) (continued)
prevalence of 482
stillbirth and 483
intrapartum factors
impact on uterine rupture 422
intrapartum FHR monitoring
fetal pulse oximetry in 508
ST segment analysis in 508
intrauterine devices (IUDs)
after induced abortion 27
levonorgestrel releasing
for fibroids 68
progesterone-containing
for HMB 16–18, 17
intrauterine fetal demise 479–85 see also stillbirth(s)
intra-uterine insemination
for unexplained subfertility 148–9
intravenous immunoglobulin (IVIg)
for patients with RPL and APS 136
in vitro fertilization (IVF) 34
for unexplained subfertility 149
iron
preparations of 336, 336
irritable bowel syndrome
diagnosis of 53
ischemic stroke
during pregnancy 317–19 see also stroke, during pregnancy
isotretinoin
for acne 207
during pregnancy 207
IUDs see intrauterine devices (IUDs)
IVF see in vitro fertilization (IVF)
IVIg see intravenous immunoglobulin (IVIg)
karyotype
abnormal fetal 133
karyotyping
parental 133
kidney(ies) see under chronic kidney disease (CKD); renal
kidney disease
chronic see chronic kidney disease (CKD)
labor see also labor and delivery
active
centimeter progression during 570
initiation of 570
arrest of 535
augmentation of 527–37 see also augmentation of labor
course of
conduction anesthesia impact on 537
defined 570
duration of
maternal age in 571
first stage of see first stage of labor
functional divisions of 534
induction of 527–34 see also induction of labor
normal progression of 569
passive 571
preterm 385–95 see also preterm labor
progression of
maternal age as factor in 570–1
obesity effects on 571
prolonged stage of
maternal or neonatal morbidity related to 536–7
prophylactic induction of
for fetal macrosomia 458, 460
protracted active phase of
oxytocin in 535–6
protracted latent phase of
management of 535
pushing during 572, 573, 572, 575
second stage of see second stage of labor
third stage of see third stage of labor
trial of 419
labor and delivery
GDM and 300
for growth-restricted fetuses 456–7
placental abruption and
timing of 412
preterm
in mothers of multiple gestations 469
spontaneous delivery
methods for 569–81 see also spontaneous delivery
timing of
PPROM management and 401
valvular lesions during pregnancy impact on 271
for women with congenital cardiac lesions
preferred methods 276
lactation
antipsychotic use during 380–1
benzodiazepine use during 381
lithium use during 381
valproate use during 381
laparoscopic cholecystectomy
for cholelithiasis in pregnancy 366–7
laparoscopic ovarian drilling
in PCOS management 125
laparoscopic surgery
in adenomyosis pain management 80
in EP management 39
laparoscopy
in adenomyosis pain management 80
in endometriosis evaluation 77
for fibroids 69
in identifying CPP causes in women 51–2
robotic-assisted
for fibroids 69
for unexplained subfertility 149–50
laparotomy
in endometriosis evaluation 77
in EP management 39
for fibroids 69
LARC methods see long-acting reversible contraception (LARC)
methods
large for gestational age (LGA)
defined 451–2
large loop excision of transformation zone (LLETZ)
in CIN management 191
laser ablation
  in CIN management  191
laser conization
  in CIN management  191
late deceleration
  defined  498, 499, 500, 500
  physiology of  502–3, 503
latency period
  PPROM management in  399
latent labor
  protracted
  management of  535
LBW see low-birthweight (LBW)
LEEP see loop electrosurgical excision procedure (LEEP)
leiomyomas
  uterine see fibroid(s)
letrozole
  for fibroids  67–8, 70
leuprolide
  for fibroids  67
levonorgestrel releasing intrauterine devices (LNG-IUDs)
  in adenomyosis pain management  79
  for fibroids  68
LGA see large for gestational age (LGA)
lifestyle modifications
  in PCOS–related infertility management  125, 126
listeriosis
  in pregnancy  348–50
lithium
  during lactation  381
  during pregnancy  206
LLETZ see large loop excision of transformation zone (LLETZ)
LMWH see low-molecular weight heparin (LMWH)
LNG-IUDs see levonorgestrel releasing intrauterine devices (LNG-IUDs)
LNG-IUS
  for HMB  16–18, 17
long-acting reversible contraception (LARC) methods  89
  candidates for  92
  in women with history of STIs  92
loop electrosurgical excision procedure (LEEP)
  in CIN management  191
low-birthweight (LBW) infants
  asthma during pregnancy and  248, 248
  multiple pregnancies and births and  472
low-dose aspirin
  in FGR management and prevention  457
low-lying placenta
  diagnosis of  408
  vasa previa related to  414
  low-lying placenta previa
diagnosis of  408
low-molecular weight heparin (LMWH)
  in thromboprophylaxis in obese women  596–7
  for VTE during pregnancy  359
L-transposition of great arteries
  D-transposition of great arteries vs.  275
Lying-in Hospitals  1
lymph node dissection
  in endometrial cancer prognosis  181–3
Lynch syndrome
  in premenopausal women with endometrial cancer  186
macrosomia  452
fetal
  prophylactic induction of labor for  458, 460
maternal adverse events associated with  452
magnesium sulfate
  in PPROM management  400
  in reducing neonatal morbidity and mortality from preterm birth  390–1
magnetic resonance–guided high-intensity focused ultrasound (MRg-FUS or MR-HIFU)
  for fibroids  68–9, 70
magnetic resonance imaging (MRI)
  for appendicitis in pregnancy  371–2, 371
  in fetal anomalies diagnostic testing  488–9
  in low-lying placenta diagnosis  408
  T1- and T2-weighted
    in endometriosis evaluation  77
major depressive disorder (MDD)
  risk factors for  378
  symptoms of  378
major depressive episode
  in pregnant women
    adverse perinatal outcomes effects of  378–9
    non-pharmacological treatments for  379–80
malformation(s)
  fetal–neonatal
    multiple pregnancies and births and  469–70
malformation syndromes
  stillbirth related to  490
malpresentation  521–4
  background  521
  defined  521
  ECV in  521
  late third trimester
    risk factors for breech presentation related to  521
  third trimester
    breech vaginal delivery vs. cesarean delivery for  521–2
    ECV for  522–3
Marfan syndrome  273, 275, 276
massage
  uterine
    in third stage of labor  576, 577
maternal age
  in labor duration  571
  in labor progress  570–1
  in length of second stage of labor  576
  in multiple pregnancies and births  468
  in uterine rupture  420–1
maternal complications  245–439 see also specific types, e.g., asthma
  AF volume disorders  443–9
  antepartum/intrapartum fetal surveillance  495–511
  APS  407–17
  APH  325–33
  asthma  247–53
  CVD  265–86
maternal complications (continued)

depression 377–84
DM 297–302
fetal anomalies 487–94
fetal growth disorders 451–65
FHR monitoring 495–511
gastrointestinal disorders 365–76
GDM 297–302
hematologic disease 335–42
hydrops fetalis 513–19
hypertensive disorders of pregnancy 255–64
infections 343–54
intrauterine fetal demise 479–85
malpresentation 521–4
multiple pregnancies and births 467–77
neurologic disease 315–24
post-term pregnancy 431–9
PPROM 397–406
psychiatric disease 377–84
renal disease 287–96
stillbirths 479–85
thyroid disease 303–14
VBAC delivery 419–30
VTE 355–63

Maternal-Fetal Medicine Unit Cesarean Registry 593
maternal position in second stage of labor 572–3
maternal serum alpha-fetoprotein (MSAFP) screening in NTDs detection
maternal subclinical hypothyroidism see subclinical hypothyroidism

McCall culdoplasty in pelvic organ prolapse management 103
MCDA placenta see monochorionic-diamniotic (MCDA) placenta
MCMA placenta see monochorionic-monoamniotic (MCMA) placenta
MDD see major depressive disorder (MDD)
medical ‘induction’ abortion 24
Medical Outcomes Study Short-Form 36 (SF-36) Health Survey 67
medicated IUDs that release levonorgestrel (LNG-IUS) for HMB 16–18
medication(s) with known teratogenic potential 206–7
in pregnancy 233–43
for asthma 249, 250
background 233
case scenario 233
clinical questions 233–9
fetal drug toxicities 238, 239
fetal risks associated with 238–9, 239, 238
pharmacokinetic changes related to placenta effects on 234–6, 235
medrol dosing schedule for
membrane sweeping in cervical ripening
memory menopause effects on 158
menopause 155–61
amenorrhea related to 112–13
bodily effects of 158
case scenario 155
clinical questions 156–9
cognitive effects of 158
defined 155
depression in 157–8
endocrinological changes associated with 156
genitourinary syndrome and 157
hypothalamic changes with 156
memory effects of 158
mood disorders in 157–8
ovarian aging with 156
overview 155
search strategy 155–6
sleep disturbances in 157
symptoms of 157
treatment of 158–9
hormonal 158–9
HRT in 158–9
indications for 158
non-hormonal 159
uterine bleeding and 157
vasomotor symptoms in 157
menorrhagia 13
menstrual bleeding abnormal 13–20 see also abnormal menstrual bleeding
heavy 13–20 see also heavy menstrual bleeding (HMB)
normal 13, 13
menstrual physiology in amenorrhea evaluation 110
mediformin in PCOS management 125
methimazone for Graves’ disease in pregnancy 309, 310
methotrexate (MTX) contraindications to 40
criteria for use 40
in EP management 40–2
metoclopramide in HG management 229
MG see myasthenia gravis (MG)
microangiopathic disorders during pregnancy 340, 340
mid-trimester induction of labor 537–8, 538
background 537
case scenario 537
clinical questions 538
secondary to lethal anomaly or fetal demise
induction of labor vs. D&E for 538, 538
termination methods 538, 538
mifepristone for fibroids 68, 70
in induced abortion 23–4
miscarriage 33–47 see also recurrent pregnancy loss (RPL)
atypical APS laboratory test results 326
background 33
case scenario 33
causes of 133
defined 131
EP vs. 39
incidence of 33
prevalence of 131
recurrent early APS and 326
misoprostol
in AMTS L 577, 577
in induced abortion 23–4
in PPH management 546–7, 547
monochorionic–diamicnion (MCDA) placenta 467
monochorionic–monoamniotic (MCMA) placenta 467
monozygotic (MZ) conceptions 467–8
mood disorders
menopause and 157–8
morbid obesity
case scenario 593
cesarean delivery in women with 593
mosaicism
amenorrhea related to 111
mother(s)
age of see maternal age
appendicitis in pregnancy risks to 372–3
cesarean delivery–related effects on 585, 586
fetal anomalies impact on 490–1
HG effects on 226
induction of labor effects on 527–30, 528
length of second stage of labor impact on 574–5
multiple pregnancies and births impact on 468–9, 469
OVD–related effects on 585, 586
post-term pregnancy risk factors for 432, 433
prolonged stage of labor effects on 536–7
MRg-FUS see magnetic resonance–guided high-intensity focused ultrasound (MRg-FUS or MR-HIFU)
MR-HIFU see magnetic resonance–guided high-intensity focused ultrasound (MRg-FUS or MR-HIFU)
MS see multiple sclerosis (MS)
MSAFP screening see maternal serum alpha-fetoprotein (MSAFP) screening
MTX see methotrexate (MTX)
multiple pregnancies and births 467–77
age as factor in 468
birthweight discordance in 472
delivery considerations 473–4
mode of delivery 474
timing of delivery 473–4
eclampsia and 468, 469
EFW in 472
fetal assessment in 472–3, 473
fetal–neonatal consequences of 469–73, 469, 471, 473
embryonic and fetal demise 470
fetal growth 472
malformations 469–70
TTTS 470–2, 471
GDM and 468, 469
growth restriction in 472
hypertensive disorders and 468, 469
maternal consequences of 468–9, 469
outcome 474–5
pre-eclampsia and 468, 469
preterm labor and delivery and 469
prevention vs. cure 475
multiple sclerosis (MS)
causes of 319
during pregnancy 319–20
background 319
case scenario 319
clinical questions 319–20
grading of evidence 320
management of 320
search strategy 320
prevalence of 315, 319
multiple sexual partners
EP related to 35
multivitamins
in HG management 229
musculo-skeletal abnormalities
in women of reproductive age with CPP 51
myasthenia gravis (MG)
during pregnancy 320–2
background 321
case scenario 320–1
clinical questions 321
delivery and fetal well-being related to 321
grading of evidence 322
search strategy 321–2
thymectomy in preventing complications 321
myomectomy
for fibroids 67, 70
MZ conceptions see monozygotic (MZ) conceptions
NAAT see nucleic acid amplification testing (NAAT)
National Institute of Child Health and Human Development (NICHD)
on FHR definitions 497–501 see also specific terms and NICHD definitions
National Institute of Child Health and Human Development (NICHD) consensus report (2008) 497, 499
National Partnership for Maternal Safety (NPMS)
on VTE prevention during pregnancy 360, 361
natural killer (NK) cells
as risk factor for RPL 135
neonate(s)
congenital heart disease in pregnant women risks to 275–6
health consequences of FGR on 458, 459
length of second stage of labor impact on 575–6
morbidity and mortality related to preterm labor– and birth–related 388, 390
multiple pregnancies and births impact on 469–73, 469, 471, 473
prolonged stage of labor effects on 536–7
valvular lesions during pregnancy effects on 271
neural tube defects (NTDs)
case scenario 201
in pregnant women
amniocentesis in detection of 220
MSAFP in detection of 219
neural tube defects (NTDs) *(continued)*
ultrasound in 219–20
prevention of
folic acid in 202–3
neurologic disease 315–24 *see also specific types*
epilepsy 315–17
introduction 315
MG 320–2
MS 319–20
in pregnancy 315–24
prevalence of 315
stroke 317–19
neuroprotection
fetal
magnesium sulfate in 400
NICHD *see* National Institute of Child Health and Human Development (NICHD)
NICHD definitions
FHR–related 497–501 *see also specific terms and fetal heart rate* (FHR) definitions
strict considerations 497
NK cells *see* natural killer (NK) cells
nodule(s)
thyroid
in pregnancy 311
nonsteroidal anti-inflammatory drugs (NSAIDs)
for HMB 16, 17
non-stress tests (NSTs)
in antepartum surveillance of growth-restricted fetuses
perinatal outcomes of 453
no-scalpel vasectomy (NSV) 93–4
NPMS *see* National Partnership for Maternal Safety (NPMS)
NSAIDs *see* nonsteroidal anti-inflammatory drugs (NSAIDs)
NSTs *see* non-stress tests (NSTs)
NSV *see* no-scalpel vasectomy (NSV)
NTDs *see* neural tube defects (NTDs)
nucleic acid amplification testing (NAAT)
in genital tract infections 56–7

obese women
cesarean delivery in 593–9 *see also* cesarean delivery, in obese women
postpartum thromboembolism in 596–7
obesity
classification of 593
defined 205
impact on length of second stage of labor 576
labor progression impacted by 571
morbid 593
preconception care in management and prevention of 205–6
prevalence of 593

OB/GYN *see* obstetrics/gynecology (OB/GYN)

obstetric emergencies 559–68
background 559
cardiopulmonary arrest 565–6
healthcare teams performance during 566
introduction 559
PE 559–65
team-oriented care for 559–68

VTE 560
obstetrics/gynecology (OB/GYN)

EBM in 1–7 *see also* evidence-based medicine (EBM), in OB/GYN

OHSS *see* ovarian hyperstimulation syndrome (OHSS)
oligohydramnios 488
ondansetron
in HG management 228, 229–30

ovarian hyperstimulation syndrome (OHSS)

open cholecystectomy
for cholelithiasis in pregnancy 366–7
operative delivery
vaginal delivery vs.

factors in second stage of labor determining 573–4, 573, 575
operative vaginal delivery (OVD) 583–91

case scenario 583
clinical options 583
decreasing trend in 583, 584, 585
evidence-based procedural aspects of 586
failed 587–8
forceps vs. vacuum 583–4, 585
future directions in 589

guideline considerations for 586
informed consent for 585
introduction 583–5, 584, 585

limitation of pulls and pop-offs in 587–8
maternal–fetal complications of 585, 586
pre-procedure checklist and clinical documentation for 585, 587, 588

prevalence of 583–5, 584, 585
quality metrics in 590

safety considerations 587–9
sequential instruments in 588–9

training, competency, and simulation in 589
ultrasound-assisted 589–90

OPK *see* over-the-counter ovulation predictor kit (OPK)

OPTIMAL trial 103

OPTIMUM trial 388

outflow tract abnormalities
amenorrhea related to 110

ovarian aging
menopause and 156

ovarian ectopic pregnancy (EP)
local therapy in 42

ovarian hyperstimulation syndrome (OHSS) 147

ovarian preservation
in women undergoing hysterectomy for endometriosis 83

ovarian removal
in endometrial cancer management in premenopausal women 184–5

ovarian stimulation
for unexplained subfertility 146–8
OVD *see* operative vaginal delivery (OVD)
over-the-counter ovulation predictor kit (OPK)
in PCOS management 125

overweight
defined 205
preconception care in management and prevention of 205–6
ovulatory infertility
PCOS and 124–5, 126
Oxford Center for Evidence-based Medicine 4
oxygen saturation
in assessing obstetric and fetal risks in women with cyanotic heart disease 275
oxygen therapy
in FGR management and prevention 457
oxytocin
in AMTSL 576–9, 576, 578
effectiveness of 579
optimum dosage of 578, 578
optimum timing of 577
vs. other medications 577
route of 578
in cervical ripening 531, 533–4
in induction of labor 531, 533–4
in PPH management 547, 547
in protracted active phase of labor 535–6
pain
pelvic see chronic pelvic pain (CPP); pelvic pain
pancreatitis
in pregnancy 367–8
paracetamol
for CPP 52
parental karyotyping
as risk factor for RPL 133
parovirus
in pregnancy 345–6
level of evidence 350
passive labor 571
PBAC see pictorial blood loss assessment chart (PBAC)
PCOS see polycystic ovarian syndrome (PCOS)
PE see pulmonary embolism (PE)
pelvic floor prolapse 101–6 see also pelvic organ prolapse
background 101
case scenario 101
pelvic organ prolapse 101–6
background 101
causes of 101
described 101–2
management of
cystoscopy during 105
pessaries in 102
surgical 102–3
types of 102–4
prevalence of 101
risk factors for 101
without SUI
management of 104–5
pelvic pain 49–54
background 49–50
case scenario 49
chronic 49–54 see also chronic pelvic pain (CPP)
PERC see Pulmonary Embolism Rule-out Criteria (PERC)
percutaneous balloon mitral commissurotomy
for valvular lesions during pregnancy 270
perimenopause defined 155
endocrinological changes associated with 156
perinatal mortality
asthma during pregnancy and 248, 248
peripartum cardiomyopathy (PPCM)
case scenario 277
clinical questions 277–80
defined 277–8
diagnosis of 278
management of 279–80
presenting features of 278
risk factors for 277–8
traditional forms of cardiomyopathy vs. 278–9
peripartum complications 525–99
augmentation of labor 534–7
cesarean delivery in obese women 593–9
induction of labor 527–34
mid-trimester induction of labor 537–8, 538
obstetric emergencies 559–68
OVD 583–91
PPH 545–57
spontaneous delivery 569–81
pessaries
in pelvic organ prolapse management 102
PGM see prothrombin G20210A (PGM)
PGS see pregestational genetic screening (PGS)
phenothiazines
in HG management 229
PICOTS 3, 3
pictorial blood loss assessment chart (PBAC) 66–7
pituitary disorders
amenorrhea related to 111–12
placenta
DC 467–8
drug therapy during pregnancy effects of 236–8, 237
low-lying
diagnosis of 408
vasa previa related to 414
MCDA 467
MCMA 467
morbidly adherent
methods in controlling/preventing hemorrhage 553–4
“rising” 408
placenta accreta 551–4
case scenario 551
clinical questions 552–4
incidence of 551
management of
hysterectomy at time of delivery in 553
risk factors for 551
placental abruption 411–13
case scenario 411
clinical questions 411–13
delivery timing with 412
expectant management for 413
prediction of 411
prevalence of 412
placental arrangement
zygosity vs. 467
placental arrangement (continued)
placental insufficiency
preterm deliver for
APS and 326–7
placenta percreta
management of 553
placenta previa 407–11
bleeding
tocolysis in management of 409
case scenario 407
clinical questions 407–11
described 407–8
diagnosis of
TVS in 408
gestational stage for delivery planning and delivery 410
low-lying
diagnosis of 408
major
home management in care of 409–10
prevalence of 407–8
“rising placenta” 408
vaginal birth in pregnancies complicated by 410
placenta previa accreta
management of 410–11
placenta previa increta
management of 410–11
placenta previa percreta
management of 410–11
placenta percreta
management of 553
placenta previa 407–11
bleeding
tocolysis in management of 409
case scenario 407
clinical questions 407–11
described 407–8
diagnosis of
TVS in 408
gestational stage for delivery planning and delivery 410
low-lying
diagnosis of 408
major
home management in care of 409–10
prevalence of 407–8
“rising placenta” 408
vaginal birth in pregnancies complicated by 410
placenta previa accreta
management of 410–11
placenta previa increta
management of 410–11
placenta previa percreta
management of 410–11
placenta percreta
management of 553
placenta previa 407–11
bleeding
tocolysis in management of 409
case scenario 407
clinical questions 407–11
described 407–8
diagnosis of
TVS in 408
gestational stage for delivery planning and delivery 410
low-lying
diagnosis of 408
major
home management in care of 409–10
prevalence of 407–8
“rising placenta” 408
vaginal birth in pregnancies complicated by 410
polycystic ovarian syndrome (PCOS) 117–29
acne and 122, 122
amenorrhea related to 112
AN and 122–3, 122
case scenario 117, 127–8
causes of 118, 119
clinical presentation of 119
clinical questions 117–27
defined 118, 118
diagnosis of 119–23, 120–2, 122
diagnostic criteria for 118, 118, 123
diagnostic tests for 123, 124, 123
differential diagnosis 123
epidemiology of 118–19
EP related to 34–5
hirsutism and 119–22, 120, 122
infertility related to
management of 125, 126
introduction 118
long-term health risks associated with
counseling on 125–6, 126
management of 123–5
anti-androgens in 124
COCs in 123–4
laparoscopic ovarian drilling in 125
lifestyle modifications in 125, 126
metformin in 125
OPK in 125
progestin-only approach in 124
SERMs in 125
weight reduction in 125
ovulatory infertility related to 124–5, 126
pregnancy complications related to 125
prevalence of 118–19
as risk factor for RPL 134
polyhydramnios
defined 443
described 443
diagnosis of
ultrasound in 444, 444
fetal anomalies detection in pregnant patients with
ultrasound in 444–5, 445
idiopathic
antenatal testing for diagnosis of fetal well-being related to 445
management of
AR in 445–6
indomethacin in 446–7, 446
perinatal outcome related to
ultrasound in detection of 444, 444
polyzygotic conceptions 467–8
postpartum care
monitoring of women with GDM 301
postpartum counseling
on long-term maternal risk of CVD 261–2
postpartum depression
case scenario 377
postpartum hemorrhage (PPH) 545–57
background 545, 545
case scenario 545
causes of 545, 545
clinical questions 546–51
general search strategy 546
introduction 545
management of 546–8, 547
arterial ligation in 549
bimanual uterine compression in 548–9
compression sutures in 549–50, 550
invasive procedures in 548–51, 550
stepwise approach to 546
systemic devascularization in 549
UAE in 550–1
uterine tamponade in 548–9
uterotonics in 546–7, 547
placenta accreta and 551–4 see also placenta accreta
quantification of 548
in third stage of labor
risk factors for 576
uterine atony and 545–51
postpartum period
self-harm and suicidal ideation in 381
postpartum pre-eclampsia
delayed
defined 256–7
postpartum thromboembolism
in obese women 596–7
postpartum thyroiditis (PPT) 308
postpartum tubal ligation 93
post-term pregnancy 431–9
case scenario 431
clinical questions 431–6
defined 431
evaluation of 434–5
introduction 431
management of
algorithm for 433, 434
complementary and alternative medicine approaches in 435–6
prenatal risks of 432, 433
risk factors for 431–2, 433
testing during 434–5
timing for delivery 432–4, 434
PPCM see peripartum cardiomyopathy (PPCM)
PPH see postpartum hemorrhage (PPH)
PPROM see preterm premature rupture of membranes (PPROM)
PPT see postpartum thyroiditis (PPT)
preconception care 201–11
aim of 201
background 202
case scenario 201
in chronic diseases management 203–6
in chronic hypertension management 204–5
defined 201
elements of 201, 208
environmental toxins–related 207–8
introduction 201
medications/teratogens in 206–7, 206
in morbidity and mortality prevention 205
for overweight and obese women 205–6
in pregestational diabetes management 203–4
rationale for 202
recreational drug use–related 207–8
substance abuse–related 207–8
preconception counseling
for women with cardiac disease 268
for women with diabetes 203–4
Preconception Health and Health Care Initiative of CDC 201, 202
prednisolone
in HG management 230
during pregnancy 207
prednisone
during pregnancy 207
pre-eclampsia 255–64
acute glomerulonephritis vs. 292
antiphospholipid antibodies and 257
atypical presentation of 256
clinical presentation of 255, 256
delayed postpartum
defined 256–7
described 255
diagnosis of
criteria in 255, 256
HELLP syndrome and 256
hypertensive disorders of pregnancy with 257
low-dose aspirin in reducing risk of 257
maternal mortality due to 248, 255–6
multiple gestations and 468, 469
postpartum counseling
CVD–related issues in 261–2
preterm delivery for
APS and 326–7
prevalence of 255
risk factors for
USPSTF on 257
with severe features
management of 260–1
superimposed
on pre-existing hypertension 258–9
pre-existing hypertension 258
superimposed pre-eclampsia on 258–9
pregabalin
for CPP 52, 53
pregestational diabetes
preconception control of 203–4
pregestational genetic screening (PGS) in RPL 140
pregnancy(ies) 274 see also pregnant women
abortion ending
prevalence of 89
acquired vascular lesions during
causes of 268
AED use during
concerns related to 316–17
pharmacokinetic changes related to 316
antiemetics in 228, 229
aortopathies in 275
APS during
management of 328–9
ASDs in 273, 274
asthma during 247–53 see also asthma
BMI during 569, 571
cardiac disease during
risk assessment models for 266–7, 266
cardiomyopathy in 277–80 see also cardiomyopathy
CIN during
management of 193
CKD in 287–96, 290 see also chronic kidney disease (CKD), in pregnant women
complications of 131
PCOS–related 125
congenital aortic disease in 276
congenital heart disease in 273–7 see also congenital heart disease
depression during 377–84 see also depression
disorders during see psychiatric disease; specific disorders, e.g., depression
DM in 297–302 see also diabetes mellitus (DM); gestational diabetes mellitus (GDM)
D-transposition of great arteries in 274, 275
ectopic 33–47 see also ectopic pregnancy (EP)
fetal thyroid disease in 310
fibroids during
evidence-based outcomes related to 65–6, 65, 66
pregnancy(ies) (continued)
gastrointestinal disorders in 
see also specific disorders and

gastrointestinal disorders, in pregnancy
genital tract infections during

clinical presentations of 59
management of 59–60
heart valves during 270–1
hemoglobin disorders during

identification and management of 336–7, 337
heterotopic 33–4
HG effects on 226
hypertensive disorders of 255–64 see also hypertensive
disorders of pregnancy
hypothyroid disease in 303–8 see also hypothyroid disease
infections in 343–54 see also specific types and
infection(s)
intrahepatic cholestasis of 368, 479, 482–3
limiting number of

counseling related to 90
major depressive episode during

adverse perinatal outcomes effects on 378–9
non-pharmacological treatments for 379–80
maternal mortality during

causes of 248
medications during 206–7, 233–43 see also specific types and
medication(s), in pregnancy
MG effects on 320–2
microangiopathic disorders during 340, 340
MS effects on 319–20
MS medications effects on 320
multiple 467–77 see also multiple pregnancies and births
neurologic disease in 315–24 see also neurologic disease
normal laboratory parameters in 288, 287
NTDs in

amniocentesis in detection of 220
MSAFP in detection of 219
second trimester ultrasound in detection of 219–20
PE during

work-up for 560–1, 560–3
physiologic changes during 233–4, 265
drug disposition effects 234–6, 235
vs. VTE 560, 561
placenta previa in 410
post-term 431–9 see also post-term pregnancy
with prior stillbirth 483–4
case scenario 483
pulmonary valve stenosis in 274–5
recreational drug use during 207–8
renal adaptations during 287–8, 288
renal disease in

types of 291–2
seizures during 315–16
smoking during 207
spacing of

counseling related to 90
stroke in 317–19 see also stroke
target capillary glucose levels in 299, 299
term 431
termination of 21–32 see also induced abortion

fetal anomalies and 490
thrombocytopenia during 339, 339–40
thyroid function effects of 303
thyroid nodule in

assessment of 311
TOF in 274
TPOAb in 305
unintended
causes of 21
contraceptive use 91, 91
prevalence of 89
valvular lesions in see valvular lesions, during pregnancy
VSDs in 274
VTE during 355–63 see also venous thromboembolism (VTE)
pregnancy-induced hypertension 257
pregnancy loss

recurrent 131–44 see also recurrent pregnancy loss (RPL)
pregnancy of unknown location (PUL) 38
Pregnancy Unique Quantification of Emesis (PUQE) questionnaire

226
pregnant women see also pregnancy(ies)

self-harm and suicidal ideation among
assessment of 381
premature birth
defined 397
prematurity
corticosteroids for 399–400
premenopausal women
endometrial cancer in

Lynch syndrome in 186
ovarian removal in management of 184–5
prognosis of 184–5
prenatal diagnosis 213–23
background 213
case scenario 213
clinical questions 213–20
in pregnant women at high risk for aneuploidy

amniocentesis 218–19
chromosome microarray analysis 219
CVS in 218
screening methods 213–14
in pregnant women with low or average risk for aneuploidy
screening methods 214–17, 214, 215
second trimester genetic ultrasound in 217–18, 217
preterm birth see also preterm labor

asthma during pregnancy and 248, 248
fetal anomalies and 490
neonatal morbidity and mortality due to 388, 390
perinatal morbidity and mortality due to 385, 397
risk factors for

FFN in identifying 387
TVS in diagnosis of 386–7
preterm cesarean birth
uterine rupture related to 420
preterm delivery
after cervical dysplasia
risk factors for 192–3
for pre-eclampsia or placental insufficiency
APS and 326–7
preterm labor 385–95 see also preterm birth
background 385
case scenarios 385
Index 625

causes of 385
clinical questions 386–92
management of
  non-pharmacologic strategies in 392
  prophylactic antibiotics in 391–2
patient at high risk for
  management of 388, 389
prevalence of
  progesterone in 387–8
risk factors for 386, 386
  diagnostic tests in identifying 386–7
spontaneous see spontaneous preterm labor tocolysis in patients presenting with 391
preterm labor and delivery
  in mothers of multiple gestations 469
preterm premature rupture of membranes (PPROM) 397–406
  background 397
  case scenario 397
  causes of 397
  complications of 397–8
  described 397
  diagnosis of 397–9
  management of 399–401
    cervical cerclage and 402
    corticosteroids in 399–400
    before fetal viability 401–2
    following invasive procedures 402
    HIV and 402
    HSV and 402
    in latency period 399
    magnesium sulfate in 400
    previable 401–2
    prophylactic antibiotics in 400
tocolysis in 400–1
  prevalence of 397
  timing of delivery in 401
preterm-related complications
  prevalence of 385
primary amenorrhea
  defined 109
  hypergonadotropic 110–11
  outflow tract abnormalities resulting in 110
prochlorperazine
  in HG management 229
progesterone
  in preterm labor and birth prevention 387–8
  for unexplained RPL 137
progesterone antagonists
  for fibroids 68
progesterone-containing intrauterine devices (IUDs)
  for HMB 16–18, 17
progestin(s)
  in endometriosis pain management 78
  in PCOS management 124
progestogen(s)
  for HMB 15, 17
  injected/depot
  for HMB 18
prolonged deceleration
  defined 498, 499, 500
physiology of 503
promethazine
  in HG management 228, 229
prophylactic antibiotics
  in PPROM management 400
  in preterm labor management 391–2
propylthiouracil (PTU)
  for Graves’ disease in pregnancy 309, 310
prostaglandins
  in cervical ripening 531, 532–3
protein C deficiency
  during pregnancy 356, 356, 357
protein S deficiency
  during pregnancy 356, 357, 357
prothrombin G20210A (PGM)
  during pregnancy 356, 356, 357
psychiatric disease
  breastfeeding by women with 380–1
  in pregnancy 377–84 see also depression
  case scenario 377
PTU see propylthiouracil (PTU)
PUL see pregnancy of unknown location (PUL)
pulmonary embolism (PE) 559–65
  case scenario 559–60
  differential diagnosis of 560, 560
  general search strategy 560
  in pregnant women
    assessment of pretest probability for 560–2, 564
    diagnosis of 357–8, 358
    maternal deaths related to 355
    work-up for 560–1, 560–3
Pulmonary Embolism Rule-out Criteria (PERC)
in assessment of pretest probability for PE during pregnancy 560–2, 564
pulmonary regurgitation
  maternal cardiovascular events related to 276
pulmonary valve stenosis
  in pregnancy 274–5
PUQE questionnaire 226
pure gonadal dysgenesis
  amenorrhea related to 111
pushing
  during labor 572, 573, 572, 575
pyridoxine
  in HG management 229
Quadruple Screen 216
quadruplet(s)
  Hellin–Zellany rule for 467
quality metrics
  in OVD 590
questions
  formulation of 3–4, 3
RCOG see Royal College of Obstetricians and Gynaecologists (RCOG)
RDS see respiratory distress syndrome (RDS)
recombinant factor VIIa (rFVIIa)
  in PPH management 547
recreational drug use
recreational drug use (continued)  26
preconception care related to  207–8
rectocele repair 104
recurrent early miscarriage
APS and  326
recurrent pregnancy loss (RPL)  131–44 see also miscarriage anticoagulant therapy for  138–40, 139 background 131 β-hCG for  135–7, 138 case scenario  131 causes of  131 clinical questions  131–41 defined  131 diagnostic tests for  132–4 confounding factors influencing proper assessment of results  137 EBM in  140–1 general search strategy  132 hormone supplementation for  137 immunotherapy for  139–40 incidence of  131 maternal risk factors for  131 PGS in  140 pregnancy after serum βhCG measurements during  135–6 prevalence of  131 prognosis in patient in interval between pregnancies  136 risk factors for  133–5 treatment options  136–41, 138, 139, 140 unexplained see unexplained RPL uterine surgery for anomalies related to  137 “refractory obstetric” APS during pregnancy management of  329–30 regurgitation pulmonary maternal cardiovascular events related to  276 Reiter’s syndrome  55–6 relaxation therapy in preterm labor management  392 renal disease  287–96 see also specific types, e.g., chronic kidney disease (CKD) case scenario  287 introduction  287 in pregnancy types of  291–2 renal system pregnancy-related adaptations in  287–8, 288 acid-base homeostasis  288 anatomic changes  287 hemodynamic adaptations  287, 288 substrate handling  287–8 renal transplant for CKD in pregnancy  293–4 reproductive physiology normal  156 respiratory distress syndrome (RDS)  2 restrictive cardiomyopathy  278–9 retained products of conception induced abortion and  26 review questions formulation of  3, 3 studies applicable to  3, 3 Revised Geneva in assessment of pretest probability for PE during pregnancy  561, 564 rFVIIa see recombinant factor VIIa (rFVIIa) Rh status in women with EP  42 “rising placenta”  408 robotic-assisted laparoscopy for fibroids  69 ROMs see rupture of membranes (ROMs) Royal College of Obstetricians and Gynaecologists (RCOG) on diagnostic tests for RPL  132 on ICP management  483 on VTE prevention during pregnancy  361 RPL see recurrent pregnancy loss (RPL) rt-tPA see thrombolytic therapy with recombinant tissue plasminogen activator (rt-tPA) rupture of membranes (ROMs) preterm premature  397–406 see also preterm premature rupture of membranes (PPROM) sacrocolpopexy in pelvic organ prolapse management  103 sacrohysterectomy in pelvic organ prolapse management  103–4 sacrospinous ligament suspension in pelvic organ prolapse management  103 safety considerations OVD–related  587–9 salpingectomy in EP management  39 salpingitis chronic EP and  35 salpingostomy in EP management  39–40 “Saving Mothers’ Lives: Confidential Enquiry into Maternal Death”  563 “Scientific Medicine”  2 SCPE Collaborative Group see Surveillance of Cerebral Palsy in Europe (SCPE) Collaborative Group secondary amenorrhea defined  109 hypergonadotropic  111 outflow tract abnormalities resulting in  110 second stage of labor ACOG on  569 clinical questions  571–6, 572–4, 573, 575 described  571 length of maternal age impact on  576 maternal outcomes related to  574–5 neonatal outcome related to  575–6 obesity effects on  576 maternal position effects in  572–3, 573
protocols and practices for vaginal delivery vs. operative delivery related to

second trimester genetic ultrasound in Trisomy 21 and Trisomy 18 detection

induced abortion in methods of screening in for pregnant women with low or average risk for aneuploidy

termination methods in ultrasound in NTDs detection in

seizure(s)

breakthrough fetal outcomes related to medications for during pregnancy teratogenicity of during pregnancy causes of EURAP on medications for

selective estrogen receptor modulators (SERMs)

for menopause in PCOS–related infertility management selective progesterone receptor modulators (SPRMs)

for fibroids selective serotonin reuptake inhibitors (SSRIs)

during pregnancy self-harm by pregnant and postpartum women

sentinel lymph node dissection (SLND)

inguinofemoral lymph node dissection vs. in early-stage vulvar cancer detection in vaginal cancer

SERMs see selective estrogen receptor modulators (SERMs)

serum β-human chorionic gonadotropin (β-hCG)

measurements of during pregnancy after RPL for patients with RPL and APS supplementation with for unexplained RPL

sexually transmitted infections (STIs)

LARC methods in women with history of SF-36 Health Survey shoulder dystocia cesarean delivery in prevention of single umbilical artery single vs. double layer closure impact on uterine rupture sinusoidal pattern defined physiology of SLE see systemic lupus erythematosus (SLE) sleep disturbances menopause and SLND see sentinel lymph node dissection (SLND)

smoking contraceptive use and EP related to during pregnancy vulvovaginal cancers related to spontaneous abortion incidence of spontaneous delivery AMTSL background clinical questions first stage of labor methods for second stage of labor third stage of labor spontaneous preterm labor causes of defined diagnosis of patient at high risk for management of prevalence of risk factors for diagnostic tests in identifying TVS in diagnosis of SPRMs see selective progesterone receptor modulators (SPRMs) squamous cell carcinoma vulvar cancer related to SSRIs see selective serotonin reuptake inhibitors (SSRIs) sterilization clinical questions counseling related to failure of female general search strategy male methods of types of sterilization failure risk factors for counseling on stillbirth(s) assessment of asthma during pregnancy and autopsy for care and delivery related to case scenario defined fetal anomalies and fetal demise as ICP and introduction pregnancies with prior prevalence of risk factors for umbilical cord in Stillbirth Collaboration Network
stress urinary incontinence (SUI)
pelvic organ prolapse without management of 104–5
stripping/sweeping membranes in post-term pregnancy management 436
stroke grading of evidence during pregnancy background case scenario clinical questions management of risk factors for search strategy ST segment analysis in intrapartum FHR monitoring subclinical hypothyroidism later development of thyroid disease and in pregnancy routine screening for T4 in subfertility causes of defined unexplained see also unexplained subfertility substance abuse preconception care related to SUI see stress urinary incontinence (SUI) suicidal ideation by pregnant and postpartum women assessment of superimposed pre-eclampsia on pre-existing hypertension Surveillance of Cerebral Palsy in Europe (SCPE) Collaborative Group suture(s) compression in PPH management systematic review processes systemic devascularization in PPH management systemic lupus erythematosus (SLE) hydroxychloroquine for T4 in T4 for subclinical hypothyroidism in pregnancy tamponade balloon in PPH management uterine in PPH management team-oriented care for obstetric emergencies TENS for transcutaneous electrical nerve stimulation (TENS) teratogen(s) most common termination of pregnancy fetal anomalies and term pregnancy defined early late tetralogy of Fallot (TOF) defined in pregnancy thioamides for Graves’ disease in pregnancy third stage of labor active vs. physiological management of defined described mean duration of oxytocin in TXA in uterine massage in third trimester polyhydramnios in ultrason in detection of thrombocytopenia during pregnancy thromboembolism postpartum in obese women venous see venous thromboembolism (VTE) thrombolytic therapy with recombinant tissue plasminogen activator (rt-tPA) for stroke during pregnancy thrombophilia(s) hereditary see hereditary thrombophilies thromboprophylaxis for cesarean delivery in obese women thromboprophylaxis bundle in VTE prevention thrombosis APS and deep vein thymectomy in prevention of MG–related complications during pregnancy thyroid disease see also specific types background case scenario diagnostic criteria for fetal later development of maternal subclinical hypothyroidism due to in pregnancy adverse effects of thyroid function pregnancy effects on thyroiditis Hashimoto’s postpartum thyroid nodule in pregnancy assessment of thyroid peroxidase antibodies (TPOAb)
Index

in pregnancy 305
thyroid stimulating hormone (TSH)
in pregnancy 303–4, 304
thyrotoxicosis 308–11 see also hyperthyroid disease
gestational transient 226
tocoly sis
for bleeding placenta previa 409
in patients presenting with preterm labor 391
in PPROM management 400–1
“To Err Is Human” 559
TOF see tetralogy of Fallot (TOF)
TOL see trial of labor (TOL)
toxicity(ies)
fetal drug 238, 239
toxin(s)
environmental
preconception care related to 207–8
TPOAb see thyroid peroxidase antibodies (TPOAb)
tranexamic acid (TXA)
in PPH management 547
in third stage of labor 578
transcervical balloon catheters
in cervical ripening 531, 532
transcutaneous electrical nerve stimulation (TENS)
in endometriosis pain management 79
transplantation
renal
for CKD in pregnancy 293–4
transvaginal ultrasound (TVS)
in adenomyosis evaluation 78
in endometriosis evaluation 77
in EP diagnosis 33, 36–8
in identifying risk factors for preterm birth 386–7
in low-lying placenta diagnosis 408
in placenta previa diagnosis 408
trial of labor (TOL)
after previous cesarean birth 419
Trial of Umbilical and Fetal Flow in Europe (TRUFFLE) 456
trichomoniasis
clinical presentations of 56
diagnosis of 57
TSH see thyroid stimulating hormone (TSH)
TXA see tranexamic acid (TXA)
TTTS see twin–twin transfusion syndrome (TTTS)
tubal ligation
postpartum 93
tubal pathology
EP related to 34–5
TVS transvaginal ultrasound (TVS)
twin(s)
ARTs and 467
congenital anomalies in 488
conjoined 467
Hellin–Zellany rule for 467
rare occurrence of 467
twin–twin transfusion syndrome (TTTS) 470–2, 471
ultrasound
in appendicitis in pregnancy 371–2, 371
in detection of perinatal outcome related to AF abnormalities 444, 444
in fetal anomalies detection in pregnant patients with polyhydramnios 444–5, 445
in fetal anomalies diagnostic testing 488–9
in NTDs detection 219–20
in polyhydramnios diagnosis in third trimester 444, 444
second trimester genetic
in Trisomy 21 and Trisomy 18 detection 217–18, 217
transvaginal see transvaginal ultrasound (TVS)
ultrasound-assisted OVD 589–90
umbilical artery(ies)
single 488
umbilical cord
in stillbirth 482
undetermined/unexplained antepartum hemorrhage (APH)
effect management for 413
unexplained infertility 145–53 see also unexplained subfertility
unexplained RPL
aspirin for 139
β-hCG for 137, 138
cytokine modulation for 140
heparins for 139, 139
hormone supplementation for 137
immunotherapy for 139–40
uterine surgery for anomalies of 137
unexplained subfertility 145–53
unexplained subfertility (continued)  145
  background  145
  case scenario  145, 150
  clinical questions  145–50
  diagnosis of  145
  general search strategy  146
  management of  145
  aromatase inhibitors in  147–8
  clomiphene citrate in  146–7
  gonadotropins in  147
  intra-uterine insemination vs. other treatment options in  148–9
  IVF vs. other treatment options in  149
    laparoscopy in  149–50
  ovarian stimulation vs. other treatment options in  146–8
  prevalence of  145
  proportion of patients who will conceive spontaneously  146
  unfractionated heparin (UFH)  358–9
  for VTE during pregnancy  358–9
  unintended pregnancy  21
  causes of  91, 91
  unresectable locally advanced vaginal cancer  177–8
  chemotherapy with radiation therapy vs. surgery for  177–8
  unresectable locally advanced vulvar cancer  177
  chemotherapy with radiation therapy vs. surgery for  177
  urinary incontinence  101–6
    stress see stress urinary incontinence (SUI)
  US Evidence-based Practice Centers (EPCs) Program  4–6
  USMEC see US Medical Eligibility Criteria (USMEC)
  US Medical Eligibility Criteria (USMEC)
    of CDC  92
  US Preventive Services Task Force (USPSTF)  4–6
    on pre-eclampsia risk factors  257
  USPSTF see US Preventive Services Task Force (USPSTF)
  uterine anomalies  134–5
  as risk factor for RPL  134–5
  uterine artery embolization (UAE)  81
    in adenomyosis pain management  81
    for fibroids  68
    in PPH management  550–1
  uterine atony  545
    case scenario  545
    PPH and  545–51
  uterine bleeding  419
    abnormal see abnormal uterine bleeding (AUB)
    dysfunctional  13
    menopause and  157
  uterine dehiscence  419
    prevalence of  419
  uterine fibroids  63–74 see also fibroid(s)
    Uterine Fibroid Symptom and Quality of Life (UFSQOL) Scale  67
    uterine incision type  422
    impact on uterine rupture  422
  uterine leiomyomas see fibroid(s)
  uterine massage  576, 577
  uterine perforation  576
  induced abortion and  25–6
  uterine prolapse  102
    management of  102
    pathology of  102
  uterine rupture  419
    antepartum factors influencing  420
    clinical questions  420–7
    defined  419
    mechanism of  419
    obstetric history factors influencing  420
    prediction of  427
    risk factors for  420–2, 423–6
    during TOL after previous cesarean birth
      larger fetus effects on  421
      maternal age effects on  420–1
    uterine tamponade  548–9
    in PPH management  548–9
    uterosacral ligament suspension  103
    in pelvic organ prolapse management
      uterotonics  546–7, 547
    vaccine(s)
      HPV  191–2
      in CIN prevention  191–2
    vacuum aspiration  23, 24
    induced abortion by  23, 24
    vacuum delivery  583–4,
      forceps delivery vs.  583–4, 585
    vacuum extraction  587
    at cesarean delivery
      safety considerations  587
    vaginal birth  419
      placenta previa and  410
    "Vaginal Birth After Cesarean: New Insights”  419
    vaginal birth after cesarean (VBAC) delivery  419–30
      background  419
      case scenario  420
      clinical questions  420–7
      prevalence of  419
    vaginal bleeding  33
      alkaline hematin for  66
      fibroids and  65
      in first trimester of pregnancy  33
      during pregnancy
        evaluation of  337–8, 338
    vaginal cancer  173–80 see also vulvovaginal cancers
      background  173
      case scenario  173, 178
      causes of  174–5
      clinical presentation of  173
      deaths related to  173
      general search strategy  173
      immunosuppression and  174–5, 174
      incidence of  174, 174
      prevalence of  173
      SLND in  177
      unresectable locally advanced
        chemotherapy with radiation therapy vs. surgery for  177–8
vaginal closure
  in uterine prolapse management 102–3
vaginal delivery
  operative 583–91 see also operative vaginal delivery (OVD)
  operative delivery vs. factors in second stage of labor determining 573–4, 575
  prior uterine rupture related to 420
vaginal pessaries
  in pelvic organ prolapse management 102
vaginal spotting
  case scenario 33
valacyclovir
  for recurrent HSV infection 58, 58
valproate
  during lactation 381
valve(s)
  artificial during pregnancy 270–1
  heart during pregnancy 270–1
valvular lesions
  causes of 268
  during pregnancy fetal and neonatal risks associated with 271
  labor and delivery methods related to 271
  management of 269–70
  maternal and obstetric risks associated with 269
  postpartum care 272–3
variable deceleration
  defined 498, 499, 500, 501
  physiology of 503
varicella zoster virus (VZV)
  in pregnancy 346–8, 347
  level of evidence 350
vasa previa 413–14
  case scenario 413
  clinical questions 413–14
  diagnosis of 413–14
  prediction of 413
  risk factors for 414
vasectomy 93–4
VBAC delivery see vaginal birth after cesarean (VBAC) delivery
venous thromboembolism (VTE)
  case scenario 355
  deaths due to 560
  imaging modalities for 561, 563
  introduction 355
  management of
    improvements in 560
    physiologic changes in pregnancy vs. 560, 561
  during pregnancy 355–63
    clinical questions 355–61
    diagnosis of 357–8, 358
    maternal deaths related to 355
    prevention of 359–61, 360
    risk factors for 355–7, 356, 357
    treatment of 358–9
  women admitted to hospital 562–5
prevention of
  ACCP on 359, 361
  thromboprophylaxis bundle in 563–4
  signs and symptoms of 560, 560
  ventilation/perfusion scanning
    for VTE in pregnancy 561, 563
ventricular septal defects (VSDs)
  in pregnancy 274
  very low–birthweight (VLBW) infants
    multiple pregnancies and births and 472
vitamin(s)
  in FGR management and prevention 457
  VLBW see very low–birthweight (VLBW)
von Willebrand disease
  bleeding in management of 338–9, 338
VSDs see ventricular septal defects (VSDs)
VTE see venous thromboembolism (VTE)
vulvar cancer 173–80 see also vulvovaginal cancers
  background 173
  case scenario 173, 178
  causes of 174–5
  clinical presentation of 173
  clinical questions 174–8
  deaths related to 173
  early-stage
    CIL in management of 175–6
    SLND vs. inguinofemoral lymph node dissection in detection of 175–7, 176
  general search strategy 173
  immunosuppression and 174–5, 174
  incidence of 174, 174
  prevalence of 173
  squamous cell carcinoma and 173
  symptoms of 173
  unresectable locally advanced chemotherapy with radiation therapy vs. surgery for 177
vulvovaginal cancers
  HPV and 174–5
  periinvasive and invasive immunosuppression and 174–5, 174
  incidence of 174, 174
VZV see varicella zoster virus (VZV)
warfarin
  fetal effects of 238, 239, 238
  during pregnancy 206
  for VTE during pregnancy 359
wart(s)
  genital 56–9
weight
  fetal
    measurements of 451
    measurements of 451
  weight reduction
    in PCOS–related infertility management 125
  well-being
    fetal in post-term pregnancy 434–5
Wells Criteria
  in assessment of pretest probability for PE during pregnancy 561–2, 564
White classification
  for DM in pregnancy 297, 298
WHO see World Health Organization (WHO)
women of reproductive age
  CPP in musculo-skeletal abnormalities with 51
World Health Organization (WHO)
  classification system on cardiac disease 267

ZAHARA risk prediction score
  for cardiac event during pregnancy 266–7, 266
Zaki labor duration
  maternal age in 571
zygosity
determination of 467–8
  placental arrangement vs. 467
zygotic splitting
  following ARTs 467